Since EGFR-TKIs were established as a first-line standard of care for EGFR-mutant NSCLC patients, several randomized clinical trials in the last decade have evaluated the efficacy of combination treatment with EGFR-TKIs and other drugs [26,27]. Here, EGFR is linked to non-small cell lung carcinoma.